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Knowledge, Motivations and Concerns about Participation in Breast Cancer
Clinical Trials in Puerto Rico
Abstract
Clinical trials (CT) in breast cancer have been crucial for new treatment discoveries. While participation in
cancer CT is low, minorities are particularly underrepresented.This study aimed toidentify factors
influencing the participation in CTs based on the experiences of Latina breast cancer survivors in Puerto
Rico (PR), especially their CT knowledge, motivations, and concerns.Method:
Method:Focus groups (FG) were
conducted by two social workers and the University of Puerto Rico/MD Anderson Community Health
Educator. Participants were stratified into two subgroups: a) women with CT experience and b) those
without CT experience. Seven FG were completed among breast cancer survivors (n=34) at two hospitals
from the PR metropolitan area. Results: Our findings showed that participants expressed a basic
knowledge and understanding of clinical trials. Motivations to participate included a desire to help others,
non-monetary incentives to participation, self-benefits, readiness to participate based on the phases of
illness, and enhanced relationships with the clinical trial recruitment team. Regardless of their previous
experience with CTs, participants expressed concerns about participation including limited of knowledge
about trial procedures and results, and lack of transportation, childcare, and support from family.
Recommendations: The barriers and motivations identified for CT participation are modifiable and best
targeted using a multidisciplinary approach.Social workers could play a potential role in participant
recruitment and retention by clarifying research protocols to potential participants, as well as conducting
CT. Our findings can help enhance capacity and training efforts for health professionals involved in CT
recruitment and retention in culturally-relevant ways.

Keywords
Breast Cancer Survivor, Clinical Trials, Latinas, Hispanic, Puerto Rico

Cover Page Footnote
Our acknowledgements to Dr. Isaac González Oncologic Hospital, HIMA San Pablo Oncologic Hospital, Dr.
Maribel Tirado-Gómez, oncologist and professor at the UPR, Medical Science Campus. Our special thanks
to those brave women that everyday fight against cancer in our country and participated in this study with
the conviction of transforming the lives of other women and cancer’s research. Also, we would recognize
the support of UPR/MDACC: Partnership for Excellence in Cancer Research Program at UPR Medical
Sciences Campus & University of Texas, MD Anderson Cancer Center; University of California UCLAHASTTP R25 DA035692; UPRMSC Post-Doctoral Master in Clinical and Translational Research Award
Number: R25MD007607. Efforts by M.A. were supported by pre-doctoral fellowships at the University of
Texas Health Science Center at Houston, School of Public Health, Susan G. Komen Traineeship in Breast
Cancer Disparities (GTDR14300827).

Authors
Marinilda Rivera-Díaz, Angélica N. García-Romero, Alelí M. Ayala-Marín, Camille Vélez-Alamo, Adrianna I.
Acevedo-Fontánez, Mariana Arévalo, and Vivian Colón-López

This article is available in Journal of Health Disparities Research and Practice: https://digitalscholarship.unlv.edu/
jhdrp/vol13/iss1/3

50 Knowledge, Motivations and Concerns about Participation in Breast Cancer Clinical Trials in
Puerto Rico
Rivera-Díaz, et al.

Journal of Health Disparities Research and Practice
Volume 13, Issue 1, Spring 2020, pp. 50-66
© 2011 Center for Health Disparities Research
School of Public Health
University of Nevada, Las Vegas

Knowledge, Motivations and Concerns about Participation in Breast
Cancer Clinical Trials in Puerto Rico
Marinilda Rivera-Díaz, MSW, PhD, MSc, University of Puerto Rico, Rio Piedras Campus
Angélica N. García-Romero, MSW, Alapás Organization
Alelí M. Ayala-Marín, MPH, University of Puerto Rico, Medical Sciences Campus
Camille Vélez-Alamo, MS, University of Puerto Rico, Medical Sciences Campus
Adrianna I. Acevedo-Fontánez, MS, University of Puerto Rico, Medical Sciences Campus
Mariana Arévalo, MSPH, University of Texas at Houston
Vivian Colón-López, PhD, University of Puerto Rico, Medical Sciences Campus
Corresponding Author:
Marinilda Rivera Díaz, MSW, Ph.D., MSc,
marinilda.riveradiaz@upr.edu
ABSTRACT
Clinical trials (CT) in breast cancer have been crucial for new treatment discoveries. While
participation in cancer CT is low, minorities are particularly underrepresented. This study aimed
to identify factors influencing the participation in CTs based on the experiences of Latina breast
cancer survivors in Puerto Rico (PR), especially their CT knowledge, motivations, and concerns.
Method: Focus groups (FG) were conducted by two social workers and the University of Puerto
Rico/MD Anderson Community Health Educator. Participants were stratified into two subgroups:
a) women with CT experience and b) those without CT experience. Seven FG were completed
among breast cancer survivors (n=34) at two hospitals located in Caguas and San Juan, PR.
Results: Our findings showed that participants expressed a basic knowledge and understanding of
clinical trials. Motivations to participate included a desire to help others, non-monetary incentives
to participation, self-benefits, readiness to participate based on the phases of illness, and enhanced
relationships with the clinical trial recruitment team. Regardless of their previous experience with
CTs, participants expressed concerns about participation including limited of knowledge about
trial procedures and results, and lack of transportation, childcare, and support from family.
Recommendations: The barriers and motivations identified for CT participation are modifiable
and best targeted using a multidisciplinary approach. Social workers could play a potential role in
participant recruitment and retention by clarifying research protocols to potential participants, as
well as conducting CT. Our findings can help enhance capacity and training efforts for health
professionals involved in CT recruitment and retention in culturally-relevant ways.
Keywords: Breast Cancer Survivor, Clinical Trials, Latinas, Hispanic, Puerto Rico
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INTRODUCTION
Clinical trials research in cancer is essential for the development of effective prevention,
diagnostic, and treatment methods. Ethnic and racial minorities and underserved populations are
particularly underrepresented in clinical trials in the United States (US) (Advani et al., 2003;
Brown, & Topcu, 2003; Ford et al., 2013; Moreno-John et al., 2004; Murthy, Krumholz, & Gross,
2004; Powell, Fleming, Walker-McGill, & Lenoir, 2008; Yancey, Ortega, & Kumanyika, 2006).
It is estimated that less than 5% of cancer patients participate in clinical trials, and that racial and
ethnic minorities are disproportionately underrepresented compared to non-Hispanic Whites
(Fracasso et al., 2013). Only 2.0–4.0% of clinical trial participants self-identify as Latino
(Kwiatkowski, Coe, Bailar, & Swanson, 2013; Parra, Karnad, & Thompson, 2014). This
underrepresentation of Latino populations in clinical trials hampers the generalizability of trial
results, such as new treatments or interventions that may be relevant to this population and
contributes to inequitable distribution of benefits and risks of trial participation among these
populations.
Researchers have explored factors influencing Latino participation in trials (Arevalo et al.,
2016; Calderón et al., 2006; Ellington, Wahab, Martin, Field, Mooney, 2006; Ford et al., 2013;
Nodora, O’Day, Yrun, & García, 2010). Results have suggested that factors associated with their
participation include knowledge, awareness, age, comorbidities, socioeconomic status, fears,
research mistrust, and logistic barriers, such as transportation and time constraints (Arevalo et al.,
2016; London et al., 2015). Studies exploring clinical trial participation in Puerto Rico (PR) are
scarce. This is despite the burden of breast cancer in PR, as well as, the controversial history of
clinical trials among Puerto Rican women (Vargas, 2017).
Breast cancer is the leading incidence and mortality cancer among Puerto Rican women.
The number of Puerto Ricans living with breast cancer in 2010 was estimated to be 13,736 women
(Centeno-Girona et al., 2013); thus, it is important to understand patients’ knowledge, barriers and
facilitators that might help or interfere with participation of Puerto Rican women in breast cancer
clinical trials. An enhanced understanding of these factors is necessary to design strategies that
will aid in increasing recruitment and retention of participants in future clinical trials. Moreover,
it is also necessary to explore whether or not these factors differ among women with and without
clinical trial experience because it could aid in identifying opportunities to increase recruitment
and retention of these two populations. The general purpose of this qualitative study was to identify
the knowledge, motivations, and concerns influencing CT participation of Latinas in PR, including
those with and without prior clinical trial participation experience. The specific aims of the study
were: a) To identify factors (individual, cultural, social, and economic) influencing clinical trial
participation and recruitment among breast cancer women survivors in PR; b). To explain issues
surrounding willingness or unwillingness to participate in Cancer clinical trials; c) To describe the
most common concerns and questions asked about an ongoing cancer clinical trial; and d) To
explore clinical trial satisfaction, and willingness or unwillingness for future participation among
breast cancer women survivors with clinical trial participation experience.
METHODS
Study Population
An interdisciplinary research team consisting of epidemiologists, social workers, and a
community health educator (CHE) recruited participants from two hospitals located in Caguas and
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San Juan, PR. Previous research collaborations existed between our research team and hospital
institutions because these institutions provide health services to women with breast cancer
diagnosis. Individuals were eligible to participate if they were: 1) Spanish speakers; 2) women; 3)
21 years of age and older, and 4) had been previously diagnosed with breast cancer. Participants
were identified by the hospitals. Those that agree to participate were subsequently referred to the
research team. Research assistants contacted women that agree to participate and confirmed the
women’s participation in this study by phone.
Study Design & Procedures
Focus groups (FG) were conducted in Spanish by two social workers and the University of
Puerto Rico/MD Anderson Community Health Educator (CHE), all of whom were trained in
qualitative methods. Two groups of breast cancer survivors were included in the FG: (1) women
who had previously participated in a clinical trial and, 2) women who had not participated. Study
participants reviewed and signed an informed consent and completed a brief survey including
questions regarding their sociodemographic, cancer clinical history, and their previous experience
with clinical trials, when applicable. Each FG had approximately five participants in each group.
Four (4) FGs were conducted with participants who had participated in clinical trials, and three (3)
FGs with participants without clinical trial participation experience. All FGs were audio recorded,
lasting approximately 90 minutes. During the FG conversations, participants were asked to share
their experiences and perceptions of clinical trials using a semi-structured interview guide
addressing as summarized in Table 1. Upon completion, each participant received an incentive of
$20.00 for their time and transportation costs. The Institutional Review Board of the University of
PR, Medical Sciences Campus reviewed and approved the study protocol.

Journal of Health Disparities Research and Practice Volume 13, Issue 1, Spring 2020
http://digitalscholarship.unlv.edu/jhdrp/
Follow on Facebook: Health.Disparities.Journal
Follow on Twitter: @jhdrp

53 Knowledge, Motivations and Concerns about Participation in Breast Cancer Clinical Trials in
Puerto Rico
Rivera-Díaz, et al.
Table 1: Questions of the FGs, and topics*
Aims:
Topics

1. Knowledge,
attitudes,
and beliefs
towards
clinical
trials

2. Motivation
towards
participating
in clinical
trials

3. Barriers and
facilitators
in clinical
trials

4. Preferences
for
obtaining
information
about
clinical
trials

Questions addressing aim
• What do you know about clinical trials?
• Have you ever been invited to participate in a breast cancer clinical
trial or other type of clinical trial?
• Would anyone like to share their experience from trials you have
participated in? (WE)
• If you were invited to participate in a clinical trial, what reasons
would motivate you to participate?
• If you are invited to participate in a clinical trial again, what reasons
would motivate you to participate? (WE)
• What opinion do you have in general about people that participate
in clinical trials?
• (An example of a clinical trial is presented to the participants of
FGs). As a result of the previously described research protocol,
what questions do you have about this clinical trial?
• If we ask you to participate in this clinical trial, what reasons would
you have to participate in this clinical trial?
• What reasons do you think could influence your decision to
participate in this clinical trial?
• What are the things that would make difficult your participation in
a clinical trial?
• What are the things that would facilitate your participation in a
clinical trial?
• Which reasons do you understand will influence your decision to
participate in a clinical trial?
• Why do you think that clinical trials are important for you and your
family?
• If you have children, what reasons would you have to register them
in a clinical trial?
• What kind of research related with cancer do you think should be
conducted in PR?
•
•

Have you ever seen or listened any social media or promotion of a
specific clinical trial? (Explore details)
Let’s assume that we want to develop educational materials to
increase the knowledge and recruitment of breast cancer survivors
in clinical trial, like the example mentioned before, what
information do you think is necessary to include in the
informational material to help people decide to participate?

* WE refers to women with clinical trial experience.

Analysis
Triangulation technique, peer debriefing, and negative case analysis were applied for
credibility as recommended in the literature (Barush, Gringeri, & George, 2011). After each FG
section, a peer debriefing short meeting was implemented to discuss systematically the FG’s
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experience and explore researchers’ perspectives and thoughts. A research assistant transcribed all
of the Spanish audio recordings of FG conversations ad verbatim, and another staff member
revised the transcripts for accuracy. After all the data was transcribed, the research team conducted
a process of triangulation of peer’s analysis (Strauss, 2003). This type of triangulation involved
five researchers from different disciplines, who were trained in coding and analyzing FGs, and
were non-blinded to the purpose of the study. They were asked to code the first two transcripts
independently, identifying major themes according to the aim of the study. Also, coders were
encouraged to identify emergent new themes. This allowed the team to confirm findings across
researchers without prior discussion (Carter et al., 2014; Denzin, 1978; UNAIDS, 2010). Then,
the team came together to determine similarities and differences in the coding process and define
themes combining the multiple discussions (Barush, Gringeri & George, 2011). Coders are
described as interdisciplinary researchers that were directly involved in the data collection process
as well other research assistants not involved. A preliminary data codebook was developed for this
initial phase of the analysis. Three specific themes were identified that contribute to understand
patients’ knowledge, barriers and facilitators that might help or interfere with participation of
Puerto Rican women in breast cancer clinical trials. Subsequent weekly research team meetings
were conducted to apply this triangulation technique with all the transcripts. If negative case
analysis emerged, it was integrated into the discussion to critically question the pattern of
responses identified among other participants. Once the group reached consensus, the thematic
data analysis was entered into the Nvivo software version 11 to begin linking codes and associate
quotations for all transcripts. Similarities and differences were intended to be identified between
groups with previous clinical trial experiences and without clinical trial experiences. This paper
organized findings into the three major themes: 1) knowledge about clinical trials; 2) motivations
to participate; and 3) concerns to participate in a trial (See table 2).
Table 2: Themes and definitions as part of the analysis
Themes

Definitions

Knowledge about
clinical trials

The information that participants had about clinical trials (ex.
definitions, descriptions about clinical trial processes, etc.).

Motivations to
participate

The elements that promote or facilitate the participation of women's
breast cancer survivors in clinical trials. In our study, it included the
reasons Latinas provided for participation in future clinical trials. It
includes the following 5 subcategories: a) help to others, b)
incentives, c) self-benefits, d) phases of illness: diagnosis, treatment,
and remission, and e) patient and clinical trial research team's
relationship.

Concerns to
participate

Issues, general concerns, or barriers to participate in clinical trials. It
includes the following 5 subcategories: a) Implications of the
experimental intervention, b) Lack of access to results, c) Lack of
knowledge of the clinical trial protocol and adverse effects, and d)
Historical memory of clinical trial experiences.
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RESULTS
Demographics
A total of seven FGs (n=34) were conducted. Four of them were conducted with
participants with clinical trial experience and three FGs with participants without clinical trial
experience. Across all the seven groups, more than the half (61.7%) of the women were married
or cohabitating; 64.7% had some years of college or a college degree; and 63.6% had an annual
household income below $34,999. More than the half of the women (64.7%) had private health
insurance (See table 3).
Breast Cancer Treatment Experiences
A vast majority (82.4%) of the women reported that they had had difficulty with medical
insurance to receive services related to their breast cancer treatment and 57.6% were currently in
breast cancer treatment at the time of study. More than the half of the women (61.7%) used their
personal car as transportation method for appointments (See table 3).
Clinical Trial Experiences
A total of 41.2% of all of the participants in the FGs had heard about clinical trials before
participating in our study, 32.4% were invited to participate in clinical trials, and more than the
half of the women (63.6%) were willing to participle in clinical trials in the future (see table 3).
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The quotations obtained during the FG are presented below according to the three main
themes used for analysis: 1) knowledge about clinical trials; 2) motivation to participate; and 3)
concern to participate. Each quotation is identified by the number of the FG.
1. Knowledge about clinical trials
In general, participants expressed that clinical trials are scientific processes in which new
treatments are developed for different illnesses. They contribute to advance the medicine and to
identify the causes of cancer. A participant with prior clinical trial experience indicated:
I do not know if I am correct, but [clinical trials] their purpose is to improve the quality of
life of a patient with cancer. Other [purpose is] research for the future. Other, it is
for…something related with these research studies, with these studies is that have something
in their hands to develop it. I mean, like the most important purpose for me is advance a cure
for cancer and advance cancer research (FG #4).
Some participants also understood how the scientific method is applied to achieve the goal of the
clinical trials. A participant without clinical trial experience expressed:
I believe that a clinical trial can be detached from a hypothesis. Because the trial comes
from a hypothesis, you seek to prove it…And depending on the results, new discoveries can
be obtained that benefit us all. Like all of the advantages that we are now enjoying with
the prescribed drugs, as these investigations also come from clinical trials. FG #8
2. Motivation to participate
Next, we present our findings about elements that participants indicated that would
promote or facilitate their participation in a breast cancer trial in five sub-categories: a) help to
others, b) incentives, c) self-benefits, d) phases of illness: diagnosis, treatment and remission, and
e) patient and clinical trial research team's relationship.
a. Help to others. Participants said that they would take part in clinical trials, if doing so
could help others, including their families. Because of their journey with breast cancer, both groups
understand the difficulties that can be experienced and they expressed it as a motivation to take
part in clinical trials. Regarding possible benefits, they expressed that if they could help prevent
cancer and find better treatments with their participation, they would do it. Other participants
expressed their gratitude towards the women that had been part of previous clinical trials, and
recognized their duty in the development of the treatments they currently receive. Two participants
in the FG with CT experience expressed the following:
In my case, I would be motivated by the same, the possibility of helping and contributing
to other patients who are disoriented. You know, for example, right now I have an aunt
that just had a biopsy and we are waiting for the results. I would like to learn a little more,
so I could help her and my family, and anyone who needs help. FG #3
In my case, I thank all the people who served and participated in clinical research. For
example, with Tamoxifen, the pill that we take in our treatments. If those women had not
participated, I would not have been beneficiated. And that's how it goes with every
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medicine that is on the market right now. So, I'm very grateful of these studies and to be
able to participate. FG #4
Participants without clinical trial experience indicated:
Well, it's hard... When you have the condition, you say: "let's go, let's do it." Honestly, if
you ask me now, I'd tell you: "Yes, I would participate in a research study." Before having
cancer, I would had told you that I would not participate; I will not be a guinea pig. But
since you go through the experience, it touches you closely and it hurts. You want to help.
You want to help other people to prevent the disease. Actually, the word is, prevention...
helping other people. I would accept it right now. If you asked me 7 months ago, no. FG
#2
b. Incentives. Incentives means something concrete or accommodations patients can
receive to motivate them to participate in clinical trials. Participants in general expressed having
access to their results during their participation to be a motivation. Neither group discussed the
need to obtain money as a priority for their participation. Other issues, such as flexibility for
scheduling clinical trial procedures, and access to results and health services, were also important
and perceived as incentives for participation. Other factors to be considered to accommodate their
participation were: employment status, geographical location, transportation, and child care. A
participant with clinical trial experience indicated:
In my experience, because I had lost a lot of work days, I could not participate of the study.
So they went to my house on a Saturday, my free day…also the schedules; why can't clinical
studies be conducted at nights or weekends? …I told her: "I really can't miss work." And
she went to my house…I think it's very difficult to leave your work area for a study, and
then go back to work if you have the time. It would have been easier for me if the study had
been at night or on a Saturday…There are many people who do not work, but if you are a
person who does, you have some responsibilities there, and in addition, you have to go to
three appointments a month…The solution is "I won't do it". FG #4
Another participant without clinical trial experience said:
Even during the time that the group is being monitored in the trials, the research team
should also be orienting them about how the study is going, how are the findings; because
that motivates the person to also continue her to participate... Because I see it as you're
trying to help me, and I'm not just another number. …you are helping me to improve and
to overcome my situation, and I contribute as well. FG #2
c. Self-benefits. Self-benefits mean something concrete patients could receive to help
improve their own health. Some participants with clinical trial experience expressed an interest in
knowing the results of their tests so that they could use them for their treatments, considering this as
a self-benefit. There was also an expectation of a reduction or elimination of treatment costs and
privilege-related priority at treatment appointments. Two participants with clinical trial experience
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expressed the importance of knowing the causes, treatments, and alternatives as a motivation to
consider their participation:
Yes, because that is important. Because you want to help to improve the situation and
promote the disclosure of the results for better treatments. But also, you would like to see
how it can help you too. FG #6
…I would participate in the study in the group of chemotherapy alone, if they offered me
an incentive that guarantees me that I will not have to wait that long for treatment. And
that because I'm part of this study, I have the benefit of having the first turn. FG #6
d. Phases of illness: Diagnosis, Treatment, and Remission. Participants with clinical trial
experience expressed concern regarding the stage of cancer in which some of them were contacted
to participate in clinical trial. They expressed, that if the reach out process was made at times when
they had overcome their negative emotions about their diagnosis, there was a higher possibility that
they would participate.
I would participate because I believe that when you already pass to that other stage, like
the one that I am at now, where you already saw what happened. Before you were the
protagonist, but now you are not, you become part of the show and you can analyze things
without being touched in a personal way. And there you have the disposition and the
knowledge of what touched you personally, and now you can sit in the other's seat…And
if you're going to invite me to a study that I can contribute something that is needed, I want
to be part of that because I have a lot to talk about. FG #6
e. Patient and clinical trial research team's relationship. Participants in both groups valued
the communication between the clinical trial research team and themselves. Women with experience
in clinical trials, expressed their satisfaction with the process by the amount and quality of the contact
kept by the team. Participants with no experience, manifested that if the conversations with the team
were constant, they would consider participation. Participants with clinical trial experience reported
that a close relationship between patients and research team was a very important element to decide
to participate in clinical trial.
…it should be done in a way that shows the humanized treatment given to the patients.
They even went to my home on New Year's Eve and took pictures of the family sharing with
the patient…Even the psychologists went, and I saw that the doctors were also involved…it
was very nice. FG #5
Also, participants of FGs without clinical trial experience focused on having a good relationship and
constant conversation with the team. As part of these conversations, they expressed their interest to
receive information about the progress of the study:
That the professionals in charge of the trial keep participants informed the whole time, not
only in the beginning, but "during the process"...I am a risk taker… I am adventurous... I
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like to investigate things... I would even dare to participate, if I have these data, updated
with a reasonable frequency. FG #8
3. Concerns to participate
Women in both subgroups expressed that there was some fear to be exposed to a new drug
with unknown effectiveness. Also, concerns about socioeconomic issues such as transportation
costs, lack of childcare (especially those taking care of grandchildren), lack of family support, and
time invested from work to participate in clinical trials (daily activities requirements from clinical
trials) were verbalized.
a. Implications of the clinical trial on their health. Most of the participants found it difficult
to decide joining a clinical trial because of the lack of information about the implications of the
clinical trial on their own health. Some expressed their concerns about co-morbidities, the
interaction of the clinical trial drug with their previous medications, and the capacity to be managed
as part of the clinical trial protocol. Two participants with clinical trial experience said:
“The same, the side effects, which I believe are worse than the remedy”. FG #3.
But I would be questioning: "What is this for?"; the pros and cons. Right now, I have to
ask about my medications, because I am allergic to aspirin and penicillin, and I developed
that after I had surgery. Now, wherever I go, I have to say it. FG #5
b. Lack of access to results. Concerns about the use of data collected in clinical trials and
not having information about the research results during and after the clinical trial is completed,
were frequently manifested as a main reason for not participating by groups with clinical trial and
without clinical trial experience. Some of the women expressed their interest to have access to the
clinical trial tests (i.e. genetic tests) that are very expensive, but are required by their doctors for
their cancer treatment’s strategy. A participant with experience said:
…I would think about it and maybe would not participate. Because you give and do not
receive. Also, you will not have access to the genetic studies that could help in the future
to solve any health situation. If I'm not going to benefit, then I don't understand, because I
believe that one has the right to receive everything that is yours. FG #4
Participant without experience:
The deductible only was more than a thousand dollars. The deductible! If we talk about the
cost, it is very high. I pay a 25%. If I'm aware that the study was already done by blood
samples, why I cannot have access to the results? Do you understand?... It must be part of
the same treatment of that patient, and not see it merely as a statistical result. It should be
as a sign of commitment to that patient, who is also undergoing through medical
improvement. FG #2
c. Lack of knowledge of the clinical trial protocol and adverse effects. Participants
manifested some concerns about the testing group that they would be assigned to in the clinical
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trial. They would not like to be exposed to some unnecessary or repeated treatment, and there
could be some hesitation to participate if they could not choose. The lack of knowledge about the
processes of the clinical trial, could be determinant to resign participation. A participant without
clinical trial experience expressed:
I would not participate, because if I will not benefit... You will not know; they will not tell
you in which group you will be... And the selection of the group is randomized.... because
that's the purpose of the study, this ... it's a difficult question. FG #2
d. Historical memory of clinical trial experiences. Even though participants without
clinical trial experience recognize that the participation of other women has been crucial for the
development of new treatments, there was a fear to be treated as guinea pigs, this is in reference
to the birth control pill trial carried out in PR in the 1950s (De Malavé, 2005) and other historical
trials implemented among Puerto Rican women.
P03: In the past it was said that we were treated like... like I am. What was it like...?
P02: Like Guinea Pigs?
P03: That! (Laughs) Guinea Pigs, because they were always experimenting with us.
(P02 & P03) FG #1
Also, some women with clinical trial experience expressed their concerns about the interests that are
behind the development of clinical trial. There was some recurrent fear of becoming guinea pigs,
and that they could be used for the economical and scientific advantage of the research team, instead
of for their health.
I am also worried, that sometimes…the primary interest is to obtain information from
patients already involved in this situation. But what kind of risks can one have as a patient
when undergoing this type of clinical trial? It favors, of course, the group that is doing the
research. We could be like guinea pigs, because the primary interest is: "Let's see how we
get information, an injection, something that provides what we want to find, the last CocaCola in the desert." Even though the people who are participating in the studies are already
patients and their lives are compromised. FG #5
DISCUSSION
This qualitative study assessed knowledge, barriers and facilitating factors to increase
clinical trial participation among Puerto Rican breast cancer survivors. The most common
motivations for participants reported were: a) help to others, b) incentives for getting access to
results, flexibility for scheduling clinical trials procedures, and health services, c) self-benefits, d)
consideration of the phases of the illness: diagnosis, treatment and remission, and e) strong patient
and clinical trial research team relationship. On the other hand, concerns about participating in
clinical trials discussed included: a) lack of access to results of clinical tests conducted during
clinical trial, b) lack of knowledge of the clinical trial protocol and possible adverse effects, c)
historical fears based on memory of clinical trial experiences in PR, and d) the notion of being
guinea pigs. As revealed by both subgroups of participants, their motivations were not directly
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related with economic benefits or incentives, but might be possibly driven by altruism, which is
different from the literature as discussed by Townsend and Cox (2013). The precarious status of the
health system in PR and lack of access to treatments for most of the chronic conditions could explain
the patients’ motivations. Clinical trials could mean a possible window for these patients to get access
to health services and innovative treatments. This finding is consistent with recent research that
concluded that low participation of Latinos in clinical trials is not due to lack of interest, but lack
of awareness about clinical trials (Arevalo et al., 2016; Lucero, Siddhartha, & Ginossar, 2017).
A crucial element for this investigation was to understand the motivations and concerns
that could increase future participation in breast cancer clinical trials of Latina women in the
context of PR. When analyzing the data, the greatest motivation that the participants expressed
was to help others, especially other women diagnosed with breast cancer. They often verbalized
the importance of giving other women hope of a good quality of life or to promote prevention to
people that have not been diagnosed. This was also represented in terms of their families and the
possible future health benefits they could obtain through their participation. In contrast with
another qualitative study about motivations to participate (e.g. Townsend, & Cox, 2013), our study
participants showed more interest in helping their families and other generations, than in getting
benefits for themselves. Other recent research studies exploring Latina participation in clinical
trials agrees with the altruism perspective (London et al., 2015). Possible explanations for the
altruistic motivation to participate in clinical trials observed in our study may be based on that the
participants were all women, and in the Latino culture matriarchal characteristics include nurturing
and taking care of others.
According to the patriarchal discourse imposed in the Latino culture, women are
adjudicated responsibilities in the private sphere or domestic/family space (Rivera-Díaz, VarasDíaz, Coriano-Ortiz, Padilla, Reyes-Estrada, & Serrano, 2015). They are socialized and taught that
they are responsible for being the caregivers, assuming this role throughout the process of
socialization at every stage of their lives. This is also evidenced in the health services scenario,
including issues regarding family approval for treatment, motherhood responsibilities versus their
health, among other concerns. A recent research study by Lucero, Siddhartha & Ginossar (2017)
sustains the idea that involving family members in the clinical trial educational process may help
participants make better decisions. In terms of clinical trial recruitment, this is an interesting
finding to consider implementing in order to increase and obtain an effective participation of
Latinas. Incentives for these women do not mean monetary benefits (London et al., 2015). Having
access to some services and flexibilities such as flexible time, child care, transportation, and
clinical interventions at home, unless medical or hospital intervention is required, are more
effective participation incentives for this population. Also, considerations for providing socioemotional support to participants depending the stage of their cancer diagnosis at the time of
recruitment and research team’s sense of empathy are highlighted. Those factors could play a
decisive role for their willingness to participate in a clinical trial.
Also, there is a reality to consider regarding the difficulty in obtaining access to health
services in the public health system in PR (Gobierno de Puerto Rico, 2005; Muñoz Sosa, Rivera
Díaz, & Correa Luna, 2018; Rivera Díaz, 2015). It is possible that breast cancer survivors would
accept to participate due to their capacity to obtain specialized health services such as laboratories,
and specialized evaluations (82.4% of the participants reported difficulties in obtain health
services), that otherwise they would not have access to. Not having access to laboratory test results
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that are part of the clinical trial could be consideration for not participating. Our findings showed
that education and continuous information about the purpose of the trial and its implications is
needed to motivate participation. Participants expressed that it would be very difficult for them to
accept participating in a clinical trial if they were not provided with a complete overview of the
study.
When addressing important factors that determine retention in clinical trials, women from
both subgroups expressed the need for open and constant communication with the clinical trial
research team. They would like to be informed on how the research is going, how it will benefit to
them, and how the objectives will be fulfilled. Physicians and the clinical trial research team should
be open to interdisciplinary work to help attain the goals of the study. The inclusion of different
professions, such as social workers, would help on the ongoing process of communication and
motivation to participate in the trial, by advocating for the patient’s rights in future research. The
social work profession has the responsibility to advocate for right to health for all individuals, in
order to promote an illness-free environment and contribute to the eradication of social
determinants that impact health. Also, social workers in clinical settings could play a potential role
for providing specific benefits information and to clarify research protocols to patients, facilitate
access to clinical trials, conduct clinical trials as researchers as well as defend the right of patients
for health information and access to new treatments through educational intervention models.
Some limitations need to be considered in this study. For future studies, inclusion criteria
should consider the stage of diagnosis of those participants without clinical trial experience.
Participants with a more recent diagnosis were more emotionally vulnerable during the FG than
those on remission or those who had finished their treatment. Also, most of the FG (6 out of 7)
were carried out in one site (hospital), this could have an effect in the variability of the experiences
reports as women coming from different regions of the country, and with different socioeconomic
and health insurance coverage backgrounds, may have had different experiences. Despite these
limitations, our study provides important qualitative data to pursue future studies which promote
retention and recruitment strategies for clinical trials in the Island. A promising endeavor given
that most of the participants (63%) reported willingness to participate in a future trials, and that
most of the barriers discussed by the participants, are manageable and best targeted using a
multidisciplinary approach.
CONCLUSION
Based on the findings, we recommend the following ten (10) considerations to recruit and
effectively retain Puerto Rican women in clinical trials: 1) Consider the personal and work-related
circumstances of the women (Ex. Productive life, job’s limitations, child care); 2) Identify benefits
and incentives, in addition to monetary incentives, that could help in recruitment and retention,
such as access to medical examinations, medical care, and clinical lab results; 3) Involve the
families in the process of recruitment, education, implementation, and culmination of clinical
trials, as it might increase the family’s support for the patient in the trial; 4) Consider the stage of
the cancer when recruiting participants and identify culturally-sensitive ways to work with them;
5) Educate survivors about the differences between standard of care for their cancer and the
implications of clinical trial procedures; 6) Develop creative strategies to explain the implications
of the clinical trial protocols to participants such as radio, non-medical journal announcements
(magazines) with clinical trial information, educational videos in medical offices, among others ;
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7) Clarify and provide information about protocols in case of adverse situations or emergencies;
8) Promote interdisciplinary work. (i.e. the social worker’s role in trial); 9) Develop protocols that
require the disclosure of study results to participants as part of the IRB protocol. This should
include publication of results in general and popular magazines using a friendly and accessible
language; and 10) Encourage the dissemination of the study results through popular access
platforms. To achieve this, as social scientists, we need to restore the confidence and eradicate the
misperceptions about clinical trials and the “guinea pig” reference from our popular memory.
Building a trustworthy relationship between research/recruitment team and patients will enhance
trust and participation of Latinas in breast cancer clinical trials. Therefore, it will contribute to the
development of effective prevention, diagnostic, and new treatment interventions, methods, and
strategies that may be culturally relevant and appropriate to this population.
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